| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11771701 | SHORLA | Methotrexate formulation |
Oct, 2034
(10 years from now) | |
| US11129833 | SHORLA | Methotrexate formulation |
Oct, 2035
(11 years from now) | |
Jylamvo is owned by Shorla.
Jylamvo contains Methotrexate.
Jylamvo has a total of 2 drug patents out of which 0 drug patents have expired.
Jylamvo was authorised for market use on 29 November, 2022.
Jylamvo is available in solution;oral dosage forms.
Jylamvo can be used as treatment of adults with severe psoriasis with an oral solution of methotrexate.
The generics of Jylamvo are possible to be released after 28 October, 2035.
Drugs and Companies using METHOTREXATE ingredient
Market Authorisation Date: 29 November, 2022
Treatment: Treatment of adults with severe psoriasis with an oral solution of methotrexate
Dosage: SOLUTION;ORAL
More Information on Dosage
JYLAMVO family patents
